Charles River Laboratories International Divests Avian Vaccine Services to Arlington Capital Partners, Establishes AVS Bio as Standalone Platform

Trending News 🌥️

Charles River Laboratories ($NYSE:CRL) International, Inc. is a global provider of contract research and drug discovery and development services to the biopharmaceutical industry. Arlington Capital Partners has purchased the Avian Vaccine Services business from Charles River Laboratories, establishing AVS Bio as a standalone platform. AVS Bio is based in Norwich, Connecticut and provides specific pathogen-free eggs and laboratory products and services for the biologic manufacturing and bioprocessing markets. Their products and services are designed to support the development, manufacture, and distribution of vaccines, therapeutics, and other biologics for both human and animal health.

This acquisition allows the company to focus on their core laboratory animal business while allowing AVS Bio to become an independent platform better suited to serve its customers. With AVS Bio now established as an independent platform, Charles River Laboratories International can focus on their core contract research and drug discovery services for the biopharmaceutical industry. This new strategic partnership will provide customers with the quality products and services they have come to expect from Charles River Laboratories International, but with the added benefit of a standalone platform tailored to their specific needs.

Market Price

The move is part of a strategic effort to establish AVS as a standalone platform, providing avian health solutions to the global poultry industry. CHARLES RIVER LABORATORIES INTERNATIONAL stock opened at $218.6 and closed at $220.1, down by 0.8% from previous closing price of 221.9. The divestment will allow CHARLES RIVER LABORATORIES INTERNATIONAL to focus on its core offerings, such as preclinical services, research models and services, and early discovery and development services. AVS will continue to serve customers with its current portfolio of inactivated and live vaccines and diagnostics for poultry health and biosecurity. This move will provide AVS with the resources and focus necessary to continue its growth and success in avian health solutions.

In addition, Arlington Capital Partners will bring their expertise in the areas of operating infrastructure, financial resources, and strategic investments to support the company’s long-term growth objectives. Going forward, the company is committed to delivering premier services and products that enable the advancement of life science and drug development initiatives. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for CRL. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for CRL. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for CRL. More…

Key Ratios Snapshot

Some of the financial key ratios for CRL are shown below. More…

VI Analysis

Charles River Laboratories International (CRLI) is a company that offers research and development services for the pharmaceutical, biotechnology and medical device industries. According to the VI Risk Rating, CRLI is a medium risk investment. This means that although the company has demonstrated strong financial performance in the past, there are certain risks that should be considered before investing. The VI App has identified two risk warnings in the balance sheet, non-financial. These include long-term debt obligations and significant capital expenditure requirements. Investors must consider these factors when assessing the company’s overall risk profile. In addition to the financial aspects, investors must also consider the company’s fundamentals and competitive environment. CRLI has a strong brand presence and a solid customer base, making it well-positioned for future growth opportunities. The competitive landscape is constantly changing, however, and investors should be aware of potential market disruptions or changes that could affect the company’s long-term prospects. Overall, CRLI represents a medium risk investment. Investors should consider all of the factors mentioned above, including financial performance, fundamentals, and competition, before deciding to invest. By doing so, they can make an informed decision and maximize their potential returns. More…

VI Peers

The global market for contract research services is growing rapidly as more and more companies are outsourcing their research and development needs. This growth is being driven by the increasing costs of R&D, the need for faster timelines, and the desire to tap into the expertise of experienced professionals. As the market expands, so does the competition, and Charles River Laboratories International Inc is up against some stiff competition from the likes of Microba Life Sciences Ltd, IDenta Corp, and Eurofins Scientific SE.

– Microba Life Sciences Ltd ($ASX:MAP)

Denta Corp is a publicly traded company that provides dental products and services. The company has a market capitalization of 1.5 million as of 2022 and a return on equity of -10.42%. The company’s products and services include dental implants, dentures, and other dental prosthetics. Denta Corp also provides dental education and training services. The company was founded in 2006 and is headquartered in New York, New York.

– IDenta Corp ($OTCPK:IDTA)

Eurofins Scientific SE is a global leader in the provision of analytical testing and scientific services. The company has a market capitalization of 13.54 billion as of 2022 and a return on equity of 12.32%. The company provides a range of services including food testing, environmental testing, pharmaceutical testing, and forensics. Eurofins Scientific SE has a network of over 800 laboratories across 47 countries.

Summary

Charles River Laboratories International is a leading global provider of preclinical and clinical research services. The company recently announced the divestiture of their Avian Vaccine Services (AVS) business to Arlington Capital Partners. This move marks Charles River’s continued focus on their core research business, while establishing AVS as a standalone platform. Charles River’s stock has seen a steady rise in the past few years, reflecting strong investor confidence in its strategic plans and long-term outlook.

The divestiture of AVS is expected to further strengthen its portfolio and improve the company’s financial performance. Investors should continue to monitor the progress of Charles River’s strategic initiatives, as well as any potential changes in the market, to gain further insight into the company’s growth prospects.